Current evidences support the inhibition of oxidative and inflammatory signaling mechanisms in the treatment of schizophrenia; as cure for this disease still remains limited. Doxycycline is a tetracycline antibiotic (a minocycline congener) with strong antioxidant and anti-inflammatory properties, and better pharmacokinetic profiles. Preclinical evidence indicates that minocycline possesses antipsychotic properties. This present study was designed to evaluate the effect of doxycycline on schizophrenia-like behaviors, as well as biomarkers of oxidative stress in mice brains. Novelty-induced rearing (NIR) behavior was used to evaluate the tranquilizing effect of doxycycline (25 - 200 mg/kg). The acute antipsychotic effects of doxycycline were assessed using apomorphine-induced stereotypy, ketamine-induced stereotypy, hyperlocomotion and enhanced immobility in forced swim test (FST). Catalepsy test was also employed to evaluate the extrapyramidal adverse effect of doxycycline in mice. The chronic antipsychotic effect of doxycycline was evaluated following oral administration of doxycycline in combination with ketamine (100 mg/kg) intraperitoneally for 10 days. Twenty four hours after the last administration, positive (locomotor activity), cognitive (Y-maze) and negative (FST) symptoms were assessed. Thereafter, levels of biomarkers of oxidative stress were evaluated in mice brains. Doxycycline significantly ( P < 0.05) decreased NIR, inhibited stereotypy induced by apomorphine and ketamine. Additionally, doxycycline significantly ( P < 0.05) prevented ketamine-induced hyperlocomotion, cognitive deficit and reduced enhanced-immobility by ketamine in mice. Furthermore, doxycycline decreased malondialdehyde concentrations in a dose-related manner. Moreover, doxycycline significantly ( P < 0.05) prevented the decrease in glutathione, and increased activities of superoxide dismutase and catalase in brain tissues. The results from this study suggest that doxycycline ameliorated schizophrenic-like behaviors via mechanisms related to attenuation of oxidative stress in mouse brain.
Tandon, R., Nasrallah, H.A. and Keshavan, M.S. (2009) Schizophrenia, “Just the Facts” 4. Clinical Features and Conceptualization. Schizophrenia Research, 110, 1-23. https://doi.org/10.1016/j.schres.2009.03.005
Picchioni, M. and Murray, M.M. (2007) Schizophrenia. British Medical Journal, 335, 91-95. https://doi.org/10.1136/bmj.39227.616447.BE
Larson, M.K., Walker, E.F. and Compton, M. (2010) Early Signs, Diagnosis and Therapeutics of the Prodromal Phase of Schizophrenia and Related Psychotic Disorders. Expert Review of Neurotherapeutics, 10, 1347-1359. https://doi.org/10.1586/ern.10.93
Pogarell, O., Koch, W., Karch, S., Dehning, S., Müller, N., Tatsch, K., Poepperl, G. and Möller, H.J. (2012) Dopaminergic Neurotransmission in Patients with Schizophrenia in Relation to Positive and Negative Symptoms. Pharmacopsychiatry, 45, 36-41. https://doi.org/10.1055/s-0032-1306313
Meltzer, H. (2010) Antipsychotic Agents & Lithium. In: Katzung, B.G., Masters, S.B. and Trevor, A.J., Eds., Basic & Clinical Pharmacology, 12th Edition, McGraw-Hill Companies, New York, 501-513.
Tandon, R., Nasrallah, H.A. and Keshavan, M.S. (2010) Schizophrenia, “Just the Facts” 5. Treatment and Prevention Past, Present, and Future. Schizophrenia Research, 122, 1-23. https://doi.org/10.1016/j.schres.2010.05.025
Dokuyucu, R., Kokacya, H., Inanir, S., Copoglu, U.S. and Erbas, O. (2014) Antipsychotic-like Effect of Minocycline in a Rat Model. International Journal of Clinical and Experimental Medicine, 7, 3354-3361.
Pazvantoglu, O., Selek, S. and Okay, I.T. (2009) Oxidative Mechanisms in Schizophrenia and Their Relationship with Illness Subtype and Symptom Profile. Psychiatry and Clinical Neuroscience, 63, 693-700. https://doi.org/10.1111/j.1440-1819.2009.02015.x
Garrido-Mesa, N., Zarzuelo, A. and Galvez, J. (2013) Minocycline: Far beyond an Antibiotic. British Journal of Pharmacology, 169, 337-352. https://doi.org/10.1111/bph.12139
Holmes, N.E. and Charles, P.G.P. (2009) Safety and Efficacy Review of Doxycycline. Clinical Medicine: Therapeutics, 1, 471-482.
Leite, L.M., Carvalho, A.G., Ferreira, P.L., Pessoa, I.X., Gonçalves, D.O., Lopes, A.A., Góes, J.G., Alves, V.C., Leal, L.K., Brito, G.A. and Viana, G.S. (2011) Anti-Inflammatory Properties of Doxycycline and Minocycline in Experimental Models: An in Vivo and in Vitro Comparative Study. Inflammopharmacology, 19, 99-110. https://doi.org/10.1007/s10787-011-0077-5
Mello, B.S, Monte, A.S., McIntyre, R.S., Soczynska, J.K., Custódio, C.S., Cordeiro, R.C., Chaves, J.H., Vasconcelos, S.M., Nobre, H.V., de Sousa, F.C.F., Hyphantis, T.N., Carvalho, A.F. and Macêdo, D.S. (2013) Effects of Doxycycline on Depressive-Like Behavior in Mice after Lipopolysaccharide (LPS) Administration. Journal of Psychiatry Research, 47, 1521-1529. https://doi.org/10.1016/j.jpsychires.2013.06.008
Monte, A.S., de Souza, G.C., McIntyre, R.S., Soczynska, J.K., dos Santos, J.V., Cordeiro, C., Ribeiro, B.M.M., de Lucena, D.F., Mendes, S.M., de Sousa, V.F., Carvalho, A.F. and Macêdo, D.S. (2013) Prevention and Reversal of Ketamine-Induced Schizophrenia Related Behavior by Minocycline in Mice: Possible Involvement of Antioxidant and Nitrergic Pathway. Journal of Psychopharmacology, 27, 1032-1043. https://doi.org/10.1177/0269881113503506
Chaudhry, I.B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S., Dunn, G. and Deakin, B. (2012) Minocycline Benefits Negative Symptoms in Early Schizophrenia: A Randomised Double-Blind Placebo-Controlled Clinical Trial in Patients on Standard Treatment. Journal of Psychopharmacology, 26, 1185-1193. https://doi.org/10.1177/0269881112444941
Wood, S.J., Yücel, M., Pantelis, C. and Berk, M. (2009) Neurobiology of Schizophrenia Spectrum Disorders: The Role of Oxidative Stress. Annals of the Academy of Medicine Singapore, 38, 396-401.
Chatterjee, M., Rajkumar, V., Surajit, G. and Gautam, P. (2012) Neurochemical and Molecular Characterization of Ketamine-Induced Experimental Psychosis Model in Mice. Neuropharmacology, 63, 1161-1171. https://doi.org/10.1016/j.neuropharm.2012.05.041
Ben-Azu, B., Aderibigbe, A.O., Adeoluwa, O.A. and Iwalewa, E.O. (2016) Ethanol Extracts of Terminalia ivorensis (Chev A.) Stem Bark Attenuates the Positive, Negative and Cognitive Symptoms of Psychosis in Experimental Animal Models. British Journal of Pharmaceutical Research, 12, 1-14. https://doi.org/10.9734/BJPR/2016/28629
Bourin, M., Poisson, L. and Larousse, C. (1986) Piracetam Interaction with Neuroleptics in Psychopharmacological Tests. Neuropsychobiology, 19, 93-96.
Chindo, B.A., Adzu, B., Tijani, A.Y. and Karniyus, S.G. (2012) Ketamine-Enhanced Immobility in Forced Swim Test: A Possible Animal Model for the Negative Symptoms of Schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38, 310-316. https://doi.org/10.1016/j.pnpbp.2012.04.018
Chatterjee, M., Singh, S., Kumari, R., Verma, A.K. and Palit, G. (2012) Evaluation of the Antipsychotic Potential of Panax quinquefolium in Ketamine Induced Experimental Psychosis Model in Mice. Neurochemical Research, 37, 759-770. https://doi.org/10.1007/s11064-011-0670-4
Omogbiya, I.A., Umukoro, S., Aderibigbe, A.O. and Adewale, G.B. (2013) Jobelyn Pretreatment Ameliorates Symptoms of Psychosis in Experimental Models. Journal of Basic Clinical Physiology and Pharmacology, 24, 331-336. https://doi.org/10.1515/jbcpp-2012-0073
Dall’igna, O.P., Fett, P. and Gomes, M.W. (2007) Caffeine and Adenosine A2a Receptor Antagonists Prevent Beta-Amyloid (25-35)-Induced Cognitive Deficits in Mice. Experimental Neurology, 203, 241-245. https://doi.org/10.1016/j.expneurol.2006.08.008
Misra, H.P. and Fridovich, I. (1972) The Role of Superoxide Anion in the Autooxidation of Epinephrine and a Simple Assay for Superoxide Dismutase. Journal of Biological Chemistry, 247, 3170-3175.
Sinha, A.K. (1972) Colorimetric Assay of Catalase. Analytical Biochemistry, 47, 389-394. https://doi.org/10.1016/0003-2697(72)90132-7
Jollow, D.J., Michell, J.R., Zampaglione, N. and Gillete, J.R. (1974) Bromobenzene-Induced Liver Necrosis. Protective Role of Glutathione an Evidence for 3,4-Bromobenzene Oxide as the Hepatotoxic Metabolite. Pharmacology, 11, 151-169. https://doi.org/10.1159/000136485
Okhawa, H., Ohishi, N. and Yagi, K. (1979) Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction. Analytical Biochemistry, 95, 351-358. https://doi.org/10.1016/0003-2697(79)90738-3
Gornall, A.G., Bardawill. C.J. and David, M.M. (1949) Determination of Serum Protein by Means of Biuret Reaction. Journal of Biological Chemistry, 177, 751-766.
Sedlak, J. and Lindsay, R.H. (1968) Estimation of Total, Protein-Bound, and Nonprotein Sulfhydryl Groups in Tissue with Ellman’s Reagent. Analytical Biochemistry, 25, 192-205. https://doi.org/10.1016/0003-2697(68)90092-4
Lieberman, J.A., Javitch, J.A. and Moore, H. (2008) Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry. American Journal of Psychiatry, 165, 931-936. https://doi.org/10.1176/appi.ajp.2008.08050769
Monji, A., Kato, T. and Kanba, S. (2009) Cytokines and Schizophrenia: Microglia Hypothesis of Schizophrenia. Psychiatry and Clinical Neurosciences, 63, 257-265. https://doi.org/10.1111/j.1440-1819.2009.01945.x
Onigbogi, O., Ajayi, A.A. and Ukponmwan, O.E. (2000) Mechanisms of Chloroquine-Induced Body Scratching Behavior in Rats: Evidence of Involvement of Endogenous Opioid Peptides. Pharmacology, Biochemistry and Behavior, 65, 333-337. https://doi.org/10.1016/S0091-3057(99)00221-X
Aderibigbe, A.O., Iwalewa, O.E., Adesina, S.K. and Agboola, O.I. (2010) Studies of Behavioral and Neural Mechanism of Aridanin Isolated from Tetrapleura tetraptera in Mice. International Journal of Pharmacology, 6, 480-486.
Geyer, M.A. and Moghaddam, B. (2002) Animal Models Relevant to Schizophrenia Disorders. Neuropsychopharmacology, 50, 690-701.
Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heniger, G.R., Bowers, M.B. and Charney, D.S. (1994) Subanaesthetic Effects of the Non Competitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. Archives of General Psychiatry, 51, 199-214. https://doi.org/10.1001/archpsyc.1994.03950030035004
Taïwe, G.S., Elisabeth, N.B., Emmanuel, T., Amadou, D., Fleur, C.O.M., Gwladys, T.N., Neteydji, S., Dabole, B., Desire, P., Dzeufietm D., Dimo, T. and De Waard, M. (2012) Antipsychotic and Sedative Effects of the Leaf Extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in Rodents. Journal of Ethnopharmacology, 143, 213-220. https://doi.org/10.1016/j.jep.2012.06.026
Irifune, M., Shimizu, T. and Nomoto, M. (1991) Ketamine-Induced Hyperlocomotion Associated with Alteration of Presynaptic Components of Dopamine Neurons in the Nucleus Accumbens of Mice. Pharmacology, Biochemistry and Behavior, 40, 399-407. https://doi.org/10.1016/0091-3057(91)90571-I
Gimenez-Llort, L., Martinez, E. and Ferre, S. (1997) Different Effects of Dopamine Antagonists on Spontaneous and NMDA-Induced Motor Activity in Mice. Pharmacology, Biochemistry and Behavior, 56, 549-553. https://doi.org/10.1016/S0091-3057(96)00295-X
Ben-Azu, B., Aderibigbe, A.O., Ajayi, A.M. and Iwalewa, E.O. (2016b) Neuroprotective Effects of the Ethanol Stem Bark Extracts of Terminalia ivorensis in Ketamine-Induced Schizophrenia-Like Behaviors and Oxidative Damage in Mice. Pharmaceutica Biology, 1-9. https://doi.org/10.1080/13880209.2016.1190382
Noda, Y., Yamada, K., Furukawa, H. and Nabeshima, T. (1995) Enhancement of Immobility in a Forced Swimming Test by Subacute or Repeated Treatment with Phencyclidine: A New Model of Schizophrenia. British Journal of Pharmacology, 116, 2531-2537. https://doi.org/10.1111/j.1476-5381.1995.tb15106.x
Anis, N.A., Berry, S.C., Burton, N.R. and Lodge, D. (1983) The Dissociative Anaesthetics, Ketamine and Phencyclidine, Selectively Reduce Excitation of Central Mammalian Neurones by N-Methyl-Aspartate. British Journal of Pharmacology, 79, 565-575. https://doi.org/10.1111/j.1476-5381.1983.tb11031.x
Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G. and Grecksch, G. (2003) Ketamine-Induced Changes in Rat Behaviour: A Possible Animal Model of Schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 27, 687-700. https://doi.org/10.1016/S0278-5846(03)00080-0
Noda, Y., Yamada, K., Furukawa, H., Nabeshima, T. (1995) Enhancement of Immobility in a Forced Swimming Test by Subacute or Repeated Treatment with Phencyclidine: A New Model of Schizophrenia. British Journal of Pharmacology, 116, 2531-2537. https://doi.org/10.1111/j.1476-5381.1995.tb15106.x
Berman, B., Perez, O.A. and Zell, D. (2007) Update on Rosacea and Anti-Inflammatory Dose of Doxycycline. Drugs of Today, 43, 27-34. https://doi.org/10.1358/dot.2007.43.1.1025697
Cazalis, J., Bodet, C., Gagnon, G. and Grenier, D. (2008) Doxycycline Reduces Lipopolysaccharide-Induced Inflammatory Mediator Secretion in Macrophage and ex Vivo Human Whole Blood Models. Journal of Periodontology, 79, 1762-1768. https://doi.org/10.1902/jop.2008.080051
Behrens, M.M. and Sejnowski, T.J. (2009) Does Schizophrenia Arise from Oxidative Dysregulation of Parvalbumin-Interneurons in the Developing Cortex? Neuropharmacology, 57, 193-200. https://doi.org/10.1016/j.neuropharm.2009.06.002
Sagara, Y. (1998) Induction of Reactive Oxygen Species in Neurons by Haloperidol. Journal of Neurochemistry, 71, 1002-1012. https://doi.org/10.1046/j.1471-4159.1998.71031002.x
Keilhoff, G., Becker, A., Grecksch, G., Wolf, G. and Bernstein, H.G. (2004) Repeated Application of Ketamine to Rats Induces Changes in the Hippocampal Expression of Parvalbumin, Neuronal Nitric Oxide Synthase and cFOS Similar to Those Found in Human Schizophrenia. Neuroscience, 126, 591-598. https://doi.org/10.1016/j.neuroscience.2004.03.039
West, A.R. and Grace, A.A. (2000) Striatal Nitric Oxide Signaling Regulates the Neuronal Activity of Midbrain Dopamine Neurons in Vivo. Journal of Neurophysiology, 83, 1796-1808.
Wood, S.J., Berger, G.E., Wellard, R.M., Proffitt, T.M., McConchie, M., Berk, M., McGorry, P.D. and Pantelis, C. (2009) Medial Temporal Lobe Glutathione Concentration in First Episode Psychosis: A 1H-MRS Investigation. Neurobiology of Disease, 33, 354-357. https://doi.org/10.1016/j.nbd.2008.11.018
Sorce, S., Schiavone, S., Tucci, P., Colaianna, M., Jaquet, V., Cuomo, V., Dubois-Dauphin, M., Trabace, L. and Krause, K.H. (2010) The NADPH Oxidase NOX2 Controls Glutamate Release: A Novel Mechanism Involved in Psychosis-Like Ketamine Responses. Journal of Neuroscience, 30, 11317-11325. https://doi.org/10.1523/JNEUROSCI.1491-10.2010
Bridges, R., Victoria, L., Doug, L. and David, A.B. (2012) Thinking outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System xc–) to Normal and Pathological Glutamatergic Signaling. Pharmacological Reviews, 64, 780-802. https://doi.org/10.1124/pr.110.003889
Ikonomidou, C. and Kaindl, A.M. (2011) Neuronal Death and Oxidative Stress in the Developing Brain. Antioxidants and Redox Signaling, 14, 1535-1550. https://doi.org/10.1089/ars.2010.3581